Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DVUC | ISIN: NZAFTE0001S4 | Ticker-Symbol:
Branche
Versorger
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
AFT PHARMACEUTICALS LIMITED Chart 1 Jahr
5-Tage-Chart
AFT PHARMACEUTICALS LIMITED 5-Tage-Chart

Aktuelle News zur AFT PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoAFT PHARMACEUTICALS LIMITED: AFT to announce full year results on May 23 2024-
DoAFT Pharmaceuticals - Maxigesic IV's Brazil entry, a foray into LATAM135AFT continues to expand its Maxigesic IV footprint with the announcement of a licensing agreement in Brazil, the largest pharma market in South America and tenth largest market globally. The deal signed...
► Artikel lesen
DiAFT PHARMACEUTICALS LIMITED: AFT Licenses Maxigesic® IV in Brazil-
MoAFT PHARMACEUTICALS LIMITED: AFT Licenses Maxigesic IV in Brazil-
23.04.AFT PHARMACEUTICALS LIMITED: AFT,Massey Ventures,Gilles McIndoe to develop scar treatmen-
22.04.AFT PHARMACEUTICALS LIMITED: AFT,Massey Ventures,Gilles McIndoe to develop scar treatment-
05.03.AFT Pharmaceuticals - Poised for international market expansion175AFT continues to focus on expanding its product portfolio and broadening its geographical footprint (including increased investments in its affiliates), which we expect to translate into stronger market...
► Artikel lesen
03.03.AFT PHARMACEUTICALS LIMITED: AFT makes further progress in international markets-
19.02.AFT Pharmaceuticals - US milestone triggers upside and guidance bump301AFT Pharmaceuticals has announced the first sale of its intravenous pain relief medicine, Maxigesic IV, through its US licensing partner, Hikma Pharmaceuticals, a material milestone for AFT's portfolio...
► Artikel lesen
15.02.AFT PHARMACEUTICALS LIMITED: AFT updates operating profit guidance to $23m to $25m-
08.02.AFT Pharmaceuticals - US maiden voyage with Maxigesic IV launch219AFT Pharmaceuticals has announced the launch of Maxigesic IV, an intravenous form of its flagship pain relief prescription medicine, in the US market by licensing partner Hikma, under the brand name...
► Artikel lesen
06.02.AFT PHARMACEUTICALS LIMITED: Maxigesic IV launched in the United States-
22.01.AFT Pharmaceuticals - Another R&D asset in the bag282AFT Pharmaceuticals has announced the addition of another candidate, HY-091, to its R&D pipeline, for the management of vulvar lichen sclerosus (VLS), a skin condition with no curative treatments available....
► Artikel lesen
18.01.AFT PHARMACEUTICALS LIMITED: AFT further broadens R&D pipeline with new product1
17.01.AFT PHARMACEUTICALS LIMITED: AFT further broadens R&D pipeline with new product candidate-
09.01.AFT PHARMACEUTICALS LIMITED: NEW YEAR LETTER TO INVESTORS-
22.12.23AFT Pharmaceuticals - R&D pipeline strengthens with new candidate367AFT Pharmaceuticals has bolstered its R&D pipeline with the addition of a new product candidate, HY-090, a locally acting novel molecule, targeting Burning Mouth Syndrome (BMS), a condition with no...
► Artikel lesen
21.12.23AFT PHARMACEUTICALS LIMITED: AFT broadens R&D pipeline with new product candidate1
27.11.23AFT Pharmaceuticals - Global growth despite tough macro environment269AFT Pharmaceuticals reported solid H124 top-line growth, driven by strong momentum in the Asian and international markets. H124 revenues of NZ$83.6m grew 27.2% from H123, bolstered by 171.4% and 47.8%...
► Artikel lesen
23.11.23NZ's AFT Pharmaceuticals eyes best day in 5 weeks on HY results-
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1